Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of Tegoprazan on Clopidogrel Pharmacodynamics
NCT06164834Phase 1Not yet recruiting
- Sponsor
- HK inno.N Corporation
- Start
- Dec 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) (3 arms), sponsored by HK inno.N Corporation. Primary endpoint: Change in P2Y12 Reaction Unit (PRU) from baseline at Day 8. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06164834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06164834.